[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516777":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":144,"collaborators":10,"id":146,"slug":10,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":147,"sex":153,"minAge":154,"maxAge":10,"enrollmentInfo":155,"targetDuration":10,"studyType":158,"phases":10,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},{"fullName":5,"class":6},"CSL Behring","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HEMGENIX",null,"Patients with hemophilia B treated with HEMGENIX in countries where HEMGENIX is approved for commercial use.",[13],"Genetic: HEMGENIX",{"label":15,"type":10,"description":16,"interventionNames":17},"FIX Prophylaxis","Patients with hemophilia B on FIX prophylaxis and enrolled in American Thrombosis and Hemostasis Network (ATHN) Transcends (A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders) Hemophilia Cohort, or a similar registry.",[18],"Biological: Factor IX (FIX)",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.",[9],[25],"Etranacogene dezaparvovec",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"BIOLOGICAL","Factor IX (FIX)","FIX prophylaxis therapy",[15],[32],{"name":33,"affiliation":5,"role":34},"Global Program Director","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Trial Registration Coordinator","CONTACT","+1 610-878-4697","clinicaltrials@cslbehring.com",[42,55,64,68,77,85,93,102,110,118,126,135],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":10},"American Thrombosis and Hemostasis Network","RECRUITING","Rochester","New York","14604","United States",{"type":50,"coordinates":51},"Point",[52,53],-77.61556,43.15478,{"lat":53,"lon":52},{"facility":56,"status":44,"city":57,"state":10,"zip":10,"country":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"Medical University Vienna","Vienna","Austria",{"type":50,"coordinates":60},[61,62],16.37208,48.20849,{"lat":62,"lon":61},{"facility":65,"status":44,"city":66,"state":10,"zip":10,"country":67,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Aarhus Universitetshospital","Århus N","Denmark",{"facility":69,"status":44,"city":70,"state":10,"zip":10,"country":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":10},"Centre Hospitalier Universitaire de Brest \u002F CHU Morvan","Brest","France",{"type":50,"coordinates":73},[74,75],-4.48628,48.39029,{"lat":75,"lon":74},{"facility":78,"status":44,"city":79,"state":10,"zip":10,"country":71,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Centre Régional de Traitement de l'Hémophilie","Nantes",{"type":50,"coordinates":81},[82,83],-1.55336,47.21725,{"lat":83,"lon":82},{"facility":86,"status":44,"city":87,"state":10,"zip":10,"country":71,"cosmosGeoPoint":88,"geoPoint":92,"contacts":10},"CHU Nancy - Hôpital Brabois","Vandœuvre-lès-Nancy",{"type":50,"coordinates":89},[90,91],6.17114,48.66115,{"lat":91,"lon":90},{"facility":94,"status":44,"city":95,"state":10,"zip":10,"country":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":10},"Klinik für Angiologie\u002F Hämostaseologie","Berlin","Germany",{"type":50,"coordinates":98},[99,100],13.41053,52.52437,{"lat":100,"lon":99},{"facility":103,"status":44,"city":104,"state":10,"zip":10,"country":96,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"University of Clinic Bonn","Bonn",{"type":50,"coordinates":106},[107,108],7.09549,50.73438,{"lat":108,"lon":107},{"facility":111,"status":44,"city":112,"state":10,"zip":10,"country":96,"cosmosGeoPoint":113,"geoPoint":117,"contacts":10},"Klinikum der Johann-Wolfgang Goethe Universitaet","Frankfurt",{"type":50,"coordinates":114},[115,116],10.53333,49.68333,{"lat":116,"lon":115},{"facility":119,"status":44,"city":120,"state":10,"zip":10,"country":96,"cosmosGeoPoint":121,"geoPoint":125,"contacts":10},"Hannover Medical School","Hanover",{"type":50,"coordinates":122},[123,124],9.73322,52.37052,{"lat":124,"lon":123},{"facility":127,"status":44,"city":128,"state":10,"zip":10,"country":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":10},"Hospital Alvaro Cunqueiro Dr. Manuel Rodriquez-Lopez","Vigo","Spain",{"type":50,"coordinates":131},[132,133],-8.72264,42.23282,{"lat":133,"lon":132},{"facility":136,"status":44,"city":137,"state":10,"zip":10,"country":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":10},"University Hospital Bern Inselspital","Bern","Switzerland",{"type":50,"coordinates":140},[141,142],7.44744,46.94809,{"lat":142,"lon":141},{"type":145,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100516777",false,"NCT06008938","An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B","IX-TEND 4001","Inclusion Criteria:\n\n* HEMGENIX Cohort:\n* \\- Treatment with commercial HEMGENIX.\n* \\- Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the participating site.\n* FIX Prophylaxis Cohort:\n* \\- Adult patients (≥ 18 years) with hemophilia B who have consented and enrolled in ATHN Transcends Hemophilia Cohort (or a similar registry) and are receiving FIX prophylaxis therapy.\n\nExclusion Criteria:\n\n* HEMGENIX Cohort:\n* \\- The patient population that will be observed in this study must not have been treated with etranacogene dezaparvovec in a clinical trial.","ALL","18 Years",{"count":156,"type":157},500,"ESTIMATED","OBSERVATIONAL","This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.",[161],"Hemophilia B",[161,9],"2026-02-18",{"date":165,"type":166},"2026-02-19","ACTUAL",{"date":168,"type":166},"2023-06-15",{"date":170,"type":157},"2043-08-01",{"name":5,"class":6},12]